 "Syngene COO Manoj Nerurkar quits, to explore start-up opportunity")
Biocon’s contract research arm Syngene International on Tuesday announced the resignation of its Chief Operating Officer Manoj Nerurkar with effect from October 1.
Nerurkar, however, will continue his association with Syngene, taking a new strategic advisory role focused on innovation across Syngene’s services. He will also pursue an external startup opportunity outside of contract research services.
The announcement of the successor will be made shortly, said the company in a regulatory filing.
Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, “Manoj has played a key role in establishing Syngene among the world’s leading Discovery and Development Services CROs. Throughout his tenure, he has actively engaged in developing the next generation of leadership talent as well as ensuring we have established world class infrastructure and capabilities.”
Prior to joining Syngene International in 2012, Nerurkar was head of project and strategic alliance management at Novartis Healthcare in Hyderabad. Before that he had an association of 11 years with global pharmaceutical company Bristol-Myers Squibb.
Nerurkar, however, will continue his association with Syngene, taking a new strategic advisory role focused on innovation across Syngene’s services. He will also pursue an external startup opportunity outside of contract research services.
The announcement of the successor will be made shortly, said the company in a regulatory filing.
Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, “Manoj has played a key role in establishing Syngene among the world’s leading Discovery and Development Services CROs. Throughout his tenure, he has actively engaged in developing the next generation of leadership talent as well as ensuring we have established world class infrastructure and capabilities.”
Prior to joining Syngene International in 2012, Nerurkar was head of project and strategic alliance management at Novartis Healthcare in Hyderabad. Before that he had an association of 11 years with global pharmaceutical company Bristol-Myers Squibb.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%